Keywords: Merck & Co, Vorapaxar, Throimbosis, TRA-2P study, Bleeding

Merck & Co vorapaxar meets goals, but raises bleeding problem

Article | 08 February 2012

Print This

US drug giant Merck & Co (NYSE: MRK) yesterday announced the top-line results of the TRA-2P (Thrombin Receptor Antagonist ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in